Share

January 15, 2019; 92 (3) ArticleOpen Access

A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis

Ramani Balu, Lindsey McCracken, Eric Lancaster, Francesc Graus, Josep Dalmau, Maarten J. Titulaer
First published December 21, 2018, DOI: https://doi.org/10.1212/WNL.0000000000006783
Full PDF
Short Form
Citation
Permissions

Make Comment

See Comments

Downloads
4202

Share

Article Information

vol. 92 no. 3 e244-e252
DOI: 
https://doi.org/10.1212/WNL.0000000000006783
PubMed: 
30578370
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received May 22, 2018
  • Accepted in final form September 5, 2018
  • First Published December 21, 2018.

Article Versions

Copyright & Usage: 
Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Ramani Balu, MD, PhD,
    2. Lindsey McCracken, MS,
    3. Eric Lancaster, MD, PhD,
    4. Francesc Graus, MD, PhD,
    5. Josep Dalmau, MD, PhD* and
    6. Maarten J. Titulaer, MD, PhD*
  1. Ramani Balu, MD, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) NIH RO1 NS082309, Co-Investigator (2) Department of Defense, W81XWH-16-2-0020, Site-PI

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Lindsey McCracken, MS,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Eric Lancaster, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) Advisory board for Grifols (2) Advisory board for Amgen (3) Advisory board for Janssen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Grifols Inc. Honoraria for teaching in courses to train their sales team about CIDP, and honoraria/travel to give a talk at the Peripheral nerve society meeting.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Medimmune Inc., fees for expert consultation. (2) Merck Inc., fees for medical-legal consultation. (3) Novartis Inc., fees for expert consultation.

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) Federal Vaccine Injury Compensation Program. Fees for expert review of cases.

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Grifols Inc. Investigator Sponsored Grant, "Antibodies to peripheral nerve proteins in GBS and CIDP", PI, 2017-2019.

    Research Support, Government Entities:

    1. (1) NINDS, K08 NS075142, PI, 2013-2017.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. (1) Rogers Towers PA, 2015, medical legal consultation. (2) Orlando Health, 2015, medical legal consultation. (3) Wilson, Elser, Moskowitz, Edelman & Dicker LLP, medical legal consultation.

  4. Francesc Graus, MD, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Josep Dalmau, MD, PhD* and
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate

    Patents:

    1. Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Advance Medical

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. -NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -Fundacio CELLEX

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun

    Royalty Payments, Technology or Inventions:

    1. Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Maarten J. Titulaer, MD, PhD*
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology: Neuroimmunology & Neuroinflammation, since June 2014

    Patents:

    1. (1) filed a patent for "methods for typing neurological disorders and cancer, and devices for use therein" specifically about diagnostics for anti-GABAB receptor antibodies and KCTD antibodies.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Medimmune LLC, research funds for serving on the scientific advisory board; (2) Guidepoint Global LLC, research funds for consultancy; (3) Novartis, research funds for teaching; (4) unrestricted research grant from Euroimmun AG.

    Research Support, Government Entities:

    1. (1) supported by the Netherlands Organisation for Scientific Research (NWO, Veni incentive and Memorabel initiative)

    Research Support, Academic Entities:

    1. (1) Previously supported by an ErasmusMC fellowship

    Research Support, Foundations and Societies:

    1. (1) supported by the Dutch Epilepsy Foundations, projectnumber 14-19.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (R.B., L.M., E.L., J.D.) and Division of Neurocritical Care (R.B.), Perelman School of Medicine, University of Pennsylvania, Philadelphia; Department of Neurology (F.G., J.D.), Hospital Clinic, University of Barcelona/Institut d'Investigacions Biomediques August Pi i Sunyer; Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain; and Department of Neurology (M.J.T.), Erasmus University Medical Center, Rotterdam, the Netherlands.
  1. Correspondence
    Prof. Dalmau josep.dalmau{at}uphs.upenn.edu
View Full Text

Article usage

Article usage: December 2018 to March 2023

AbstractFullPdfSource
Dec 20184590113Highwire
Jan 2019357716423Highwire
Feb 201948608269Highwire
Mar 201948340147Highwire
Apr 201926457111Highwire
May 201930391140Highwire
Jun 20193135698Highwire
Jul 20192224993Highwire
Aug 20192426883Highwire
Sep 20192920370Highwire
Oct 20191327570Highwire
Nov 20193222390Highwire
Dec 20191318471Highwire
Jan 20201922363Highwire
Feb 20202222286Highwire
Mar 20201317357Highwire
Apr 20201419085Highwire
May 202018138110Highwire
Jun 20201915988Highwire
Jul 20201114255Highwire
Aug 20201210154Highwire
Sep 20202312959Highwire
Oct 20201721261Highwire
Nov 20201913551Highwire
Dec 20201115557Highwire
Jan 202117148110Highwire
Feb 20211115064Highwire
Mar 2021515150Highwire
Apr 2021913561Highwire
May 20211515849Highwire
Jun 2021916637Highwire
Jul 20211518676Highwire
Aug 20211118261Highwire
Sep 2021922136Highwire
Oct 20211022177Highwire
Nov 2021723764Highwire
Dec 2021723477Highwire
Jan 20228290120Highwire
Feb 202210223113Highwire
Mar 20221220276Highwire
Apr 20221611271Highwire
May 202288748Highwire
Jun 202288148Highwire
Jul 2022127143Highwire
Aug 2022107240Highwire
Sep 2022910558Highwire
Oct 2022178156Highwire
Nov 20221814139Highwire
Dec 2022107943Highwire
Jan 2023109542Highwire
Feb 20231111839Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles